ClinicalTrials.gg
RecruitingNCT05279001Updated Mar 21, 2024

A Safety and Tolerability Study of Jaktinib

A Phase 1 interventional study of Jaktinib Hydrochloride Tablet in Myelofibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing jaktinib in Primary Myelofibrosis — 4 open to participants now, 4 under way, none of them phase 3. jaktinib · Primary Myelofibrosis.

Planned enrollment
8th of 10
26 · median 37
Started
2024
the only one that year
Phase 1
2 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
7 of 10
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 10 studies testing jaktinib in Primary Myelofibrosis, this one is the 8th largest by planned enrollment, is the only one that started in 2024, is one of 2 in phase 1, and was the 6th registered.

Primary Myelofibrosis

626 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

4 of the 10 studies testing jaktinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About jaktinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing jaktinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Read the detailed description

This study is a Phase 1, single-arm, open-label, dose escalation trial, to evaluate the safety and tolerability of Jaktinib in patients with PMF or Post-PV/ET MF and who are relapsed/refractory to a marketed JAK inhibitor

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
  • to a marketed (FDA approved) JAK inhibitor.
  • At least 18 years of age.
  • PS 0, 1, or 2.
  • Expected is greater than 24 weeks.

Exclusion criteria

Exclusion Criteria:

  • Any chemotherapy, immunomodulatory therapy, therapy, , or growth factor treatment within 14 days prior to initiation of study drug.
  • Major surgery or radiation therapy within 28 days prior to initiation of study drug.
  • With suspected allergies to jaktinib or its .
  • Another clinical trial of a new drug or medical instrument within 3 months before screening.
  • Females who are pregnant, currently breastfeeding, planning to become pregnant.
  • Unable to adopt effective methods during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Jaktinib

    Drug: Jaktinib Hydrochloride Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of jaktinib hydrochloride tablets

    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    Time frame: At least 24 weeks, up to approximately 1 year for follow-up

  2. Dose-limiting toxicities (DLTs) of jaktinib hydrochloride tablets

    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    Time frame: 28 days

Secondary outcomes

  1. Efficacy of jaktinib hydrochloride tablets

    reduction of spleen volume of ≥35%

    Time frame: at least 24 weeks, up to approximately 1 year

  2. Efficacy of jaktinib hydrochloride tablets

    reduction of total symptoms score (TSS) of ≥50%

    Time frame: at least 24 weeks, up to approximately 1 year

  3. Pharmacokinetic characteristics of jaktinib hydrochloride tablets

    Peak Plasma Concentration (Cmax)

    Time frame: 7 days

  4. Pharmacokinetic characteristics of jaktinib hydrochloride tablets

    Time to maximum concentration (Tmax)

    Time frame: 7 days

  5. Pharmacokinetic characteristics of jaktinib hydrochloride tablets

    Half-life (T1/2)

    Time frame: 7 days

  6. Pharmacokinetic characteristics of jaktinib hydrochloride tablets

    Clearance (CL/F)

    Time frame: 7 days

  7. Pharmacokinetic characteristics of jaktinib hydrochloride tablets

    Area under Curve (AUCinf)

    Time frame: 7 days

  8. Pharmacokinetic characteristics of jaktinib hydrochloride tablets

    Volume of distribution

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Site 01
    Canton, Ohio 44718, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for May 2025, 10 months later.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
Mar 15, 2022
StartEst.
Jul 1, 2024
Primary completionEst.
May 31, 2025
CompletionEst.
Nov 30, 2025
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05279001
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Jul 1, 2024 (estimated)
Primary completion
May 31, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Mar 21, 2024

Study contacts

Jason Wu, M.D
Contact
wujs@zelgen.com
+86-21-58942758

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion